These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 37863710)

  • 1. Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
    Lamas NJ; Lassalle S; Martel A; Nahon-Estève S; Macocco A; Zahaf K; Lalvee S; Fayada J; Lespinet-Fabre V; Bordone O; Pedeutour F; Baillif S; Hofman P
    Pathology; 2023 Dec; 55(7):929-944. PubMed ID: 37863710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
    Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
    JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma.
    Gelmi MC; Gezgin G; van der Velden PA; Luyten GPM; Luk SJ; Heemskerk MHM; Jager MJ
    Invest Ophthalmol Vis Sci; 2023 Dec; 64(15):36. PubMed ID: 38149971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas.
    Han LM; Lee KW; Uludag G; Seider MI; Afshar AR; Bloomer MM; Pekmezci M
    Mod Pathol; 2023 Apr; 36(4):100081. PubMed ID: 36788079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
    Field MG; Decatur CL; Kurtenbach S; Gezgin G; van der Velden PA; Jager MJ; Kozak KN; Harbour JW
    Clin Cancer Res; 2016 Mar; 22(5):1234-42. PubMed ID: 26933176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
    Schefler AC; Koca E; Bernicker EH; Correa ZM
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients.
    Kumar N; Singh MK; Singh L; Lomi N; Meel R; Pushker N; Sen S; Kashyap S
    Hum Cell; 2023 Jan; 36(1):342-352. PubMed ID: 36282437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
    Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
    Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki67 is a better marker than PRAME in risk stratification of BAP1-positive and BAP1-loss uveal melanomas.
    Donizy P; Spytek M; Krzyziński M; Kotowski K; Markiewicz A; Romanowska-Dixon B; Biecek P; Hoang MP
    Br J Ophthalmol; 2024 Jun; 108(7):1005-1010. PubMed ID: 37734766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
    Figueiredo CR; Kalirai H; Sacco JJ; Azevedo RA; Duckworth A; Slupsky JR; Coulson JM; Coupland SE
    J Pathol; 2020 Apr; 250(4):420-439. PubMed ID: 31960425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive review of PRAME and BAP1 in melanoma: Genomic instability and immunotherapy targets.
    Aljabali AAA; Tambuwala MM; El-Tanani M; Hassan SS; Lundstrom K; Mishra V; Mishra Y; Hromić-Jahjefendić A; Redwan EM; Uversky VN
    Cell Signal; 2024 Dec; 124():111434. PubMed ID: 39326690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas.
    Ahmadian SS; Dryden IJ; Naranjo A; Toland A; Cayrol RA; Born DE; Egbert PS; Brown RA; Mruthyunjaya P; Lin JH
    Ocul Oncol Pathol; 2022 Jun; 8(2):133-140. PubMed ID: 35959159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma.
    Issam Salah NEI; Marnissi F; Lakhdar A; Karkouri M; ElBelhadji M; Badou A
    Front Immunol; 2023; 14():1225140. PubMed ID: 37662962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMPREHENSIVE MOLECULAR PROFILING OF UVEAL MELANOMA EVALUATED WITH GENE EXPRESSION PROFILING, PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA EXPRESSION, AND NEXT-GENERATION SEQUENCING.
    Alsoudi AF; Skrehot HC; Chévez-Barrios P; Divatia M; De La Garza M; Bretana ME; Schefler AC
    Retina; 2024 Sep; 44(9):1580-1589. PubMed ID: 39167579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma.
    Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J
    Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.
    Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US
    Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma.
    Patrone S; Maric I; Rutigliani M; Lanza F; Puntoni M; Banelli B; Rancati S; Angelini G; Amaro A; Ligorio P; Defferrari C; Castagnetta M; Bandelloni R; Mosci C; DeCensi A; Romani M; Pfeffer U; Viaggi S; Coviello DA
    Genes Chromosomes Cancer; 2018 Aug; 57(8):387-400. PubMed ID: 29689622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.
    Field MG; Durante MA; Decatur CL; Tarlan B; Oelschlager KM; Stone JF; Kuznetsov J; Bowcock AM; Kurtenbach S; Harbour JW
    Oncotarget; 2016 Sep; 7(37):59209-59219. PubMed ID: 27486988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 15-Gene Expression Profile and
    Harbour JW; Correa ZM; Schefler AC; Mruthyunjaya P; Materin MA; Aaberg TA; Skalet AH; Reichstein DA; Weis E; Kim IK; Fuller TS; Demirci H; Piggott KD; Williams BK; Shildkrot E; Capone A; Oliver SC; Walter SD; Mason J; Char DH; Altaweel M; Wells JR; Duker JS; Hovland PG; Gombos DS; Tsai T; Javid C; Marr BP; Gao A; Decatur CL; Dollar JJ; Kurtenbach S; Zhang S
    J Clin Oncol; 2024 Oct; 42(28):3319-3329. PubMed ID: 39052972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma.
    Cai L; Paez-Escamilla M; Walter SD; Tarlan B; Decatur CL; Perez BM; Harbour JW
    Am J Ophthalmol; 2018 Nov; 195():154-160. PubMed ID: 30092184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.